デジタルセラピューティクス(DTx)の世界市場(~2026年):用途別(前糖尿病、栄養、ケア、糖尿病、CVD、CNS、CRD、MSD、GI、薬物乱用、リハビリテーション)、販売チャネル別(B2C、患者、介護者、B2B、提供者、支払者、雇用者、製薬会社)

■ 英語タイトル:Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global Forecasts to 2026

調査会社MarketsandMarkets社が発行したリサーチレポート(データ管理コード:HIT4407)■ 発行会社/調査会社:MarketsandMarkets
■ 商品コード:HIT4407
■ 発行日:2021年7月20日
■ 調査対象地域:グローバル
■ 産業分野:医療
■ ページ数:198
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール(受注後24時間以内)
■ 販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥732,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥984,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,206,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[デジタルセラピューティクス(DTx)の世界市場(~2026年):用途別(前糖尿病、栄養、ケア、糖尿病、CVD、CNS、CRD、MSD、GI、薬物乱用、リハビリテーション)、販売チャネル別(B2C、患者、介護者、B2B、提供者、支払者、雇用者、製薬会社)]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

マーケッツアンドマーケッツ社は、デジタルセラピューティクス(DTx)の世界市場規模が2021年34億ドルから2026年131億ドルまで、年平均31.4%成長すると予測しています。本調査レポートは、世界のデジタルセラピューティクス(DTx)市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、用途別(治療/ケア関連、予防)分析、販売チャネル別(B2B、B2C)分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・デジタルセラピューティクス(DTx)の世界市場規模:用途別(治療/ケア関連、予防)
・デジタルセラピューティクス(DTx)の世界市場規模:販売チャネル別(B2B、B2C)
・デジタルセラピューティクス(DTx)の世界市場規模:地域別
・競争状況
・企業情報

“The global digital therapeutics market is projected to reach USD 13.1 billion by 2026 from USD 3.4billion in 2021, at a CAGR of 31.4%.”
Growth in this market is primarily driven by the increasing incidence of preventable chronic diseases, the need to control healthcare costs, rising focus on preventive healthcare, and rising investments in digital therapeutics. However, a lack of awareness and access to digital therapeutics programs in developing countries, resistance from traditional healthcare providers, and unstable payment models are challenging the growth of this market.

“Treatment/care-related applications segment accounted for the largest share of the digital therapeutics market in 2020”
Based on application, the digital therapeutics market is segmented into preventive and treatment/care-related applications. The large share of this segment is attributed to the growing incidences of chronic diseases, the rising economic burden of their treatment, and investments in digital therapeutics to encourage the development of cost-effective and scalable treatment platforms for these conditions.

“Diabetes segment is expected to dominate the market”
Based on the type of treatment/care-related application, the digital therapeutics market is further segmented into diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications. Diabetes commanded the largest share of 19.0% of the digital therapeutics market for treatment/care-related applications in 2020. The growing prevalence of diabetes, high healthcare costs associated with diabetes, and increasing government initiatives to reduce the burden with the help of cost-effective solutions are expected to drive the market growth in this segment.

“B2B segment is expected to grow at the highest CAGR during the forecast period.”
Based on the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). This is attributed to growing awareness among providers, payers, and employers about the benefits of digital therapeutics and the inclination of pharmaceutical companies to integrate digital therapeutics with their drug products.

“North America to be the largest and the fastest-growing regional market”
North America, which comprises the US and Canada, forms the largest market for digital therapeutics.Factors such as the influx of new startups, increasing investments in digital therapeutics, improvements in the reimbursement structure for digital therapeutics, and government initiatives to support technological advancements drive market growth in this region.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 (50%), Tier 2 (30%), and Tier 3 (20%)
• By Designation: C-level (75%), D-level (15%), and Others (10%)
• By Region: North America (70%), Europe (20%), APAC (7%), and the RoW(3%)

List of Companies Profiled in the Report
• Noom (US)
• Livongo Health (US)
• Omada Health (US)
• WellDoc (US)
• Pear Therapeutics (US)
• Proteus Digital Health (US)
• Propeller Health (US)
• Akili Interactive Labs (US)
• Better Therapeutics (US)
• Happify (US)
• Kaia Health (Germany)
• Mango Health (US)
• Click Therapeutics (US)
• Canary Health (US)
• Wellthy Therapeutics (India)
• Cognoa (US)
• Ayogo Health (Canada)
• Mindstrong Health (US)
• 2Morrow (US)
• Ginger (US)
• BehaVR Inc., (US)
• Mindable Health (Germany)
• Virta Health (US)
• Hinge Health (US)
• Doktor.se (Sweden)

Research Coverage:
This report provides a study of the digital therapeutics market. It aims at estimating the size and future growth potential of the market across different segments, such as sales channel, application, and region.The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of revenue numbers for the overall digital therapeutics market and its subsegments. This report will also help stakeholders understand the competitive landscape, gain insights to position their business,and make suitable go-to-market strategies. It will also enable stakeholders to gauge the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

*** レポート目次(コンテンツ)***

1 INTRODUCTION 28
1.1 OBJECTIVES OF THE STUDY 28
1.2 MARKET DEFINITION 28
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.2.2 MARKETS COVERED 29
1.2.3 YEARS CONSIDERED FOR THE STUDY 30
1.3 CURRENCY 30
1.4 LIMITATIONS 30
1.5 STAKEHOLDERS 31
1.6 LIMITATIONS 31
1.7 SUMMARY OF CHANGES 31
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 34
2.1.2 PRIMARY DATA 35
FIGURE 2 PRIMARY SOURCES 35
2.1.2.1 Key data from primary sources 36
FIGURE 3 KEY INDUSTRY INSIGHTS 37
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 38
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION 38
2.2 MARKET SIZE ESTIMATION 39
2.2.1 BOTTOM-UP APPROACH 39
2.2.1.1 Approach one: revenue mapping-based estimation 39
FIGURE 6 ESTIMATION OF THE DIGITAL THERAPEUTICS MARKET: REVENUE MAPPING-BASED ESTIMATION 40
2.2.1.2 Approach two: Buyer adoption-based estimation 40
FIGURE 7 MARKET SIZE ESTIMATION: BUYER ADOPTION-BASED ESTIMATION 40
2.2.2 TOP-DOWN APPROACH: PENETRATION RATE-BASED MARKET SIZE ESTIMATION 41
FIGURE 8 PENETRATION RATE-BASED MARKET ESTIMATION 41
2.2.3 GROWTH FORECAST 41
TABLE 1 FACTOR ANALYSIS 42
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 9 DATA TRIANGULATION METHODOLOGY 43
2.4 MARKET PLAYER RANKING 44
2.5 ASSUMPTIONS FOR THE STUDY 44
3 EXECUTIVE SUMMARY 45
FIGURE 10 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2021 VS. 2026 (USD MILLION) 45
FIGURE 11 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
2021 VS. 2026 (USD MILLION) 46
FIGURE 12 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL: PAYERS HOLD THE LARGEST MARKET SHARE 47
FIGURE 13 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (2021–2026) 48
FIGURE 14 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, 2021 VS. 2026 (USD MILLION) 48
FIGURE 15 GEOGRAPHICAL SNAPSHOT OF THE DIGITAL THERAPEUTICS MARKET 49
4 PREMIUM INSIGHTS 50
4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW 50
FIGURE 16 INCREASING INCIDENCE OF CHRONIC DISEASES & TECHNOLOGICAL ADVANCEMENTS ARE DRIVING THE ADOPTION OF DIGITAL THERAPEUTICS 50
4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 51
FIGURE 17 B2B SALES DOMINATE THE DIGITAL THERAPEUTICS MARKET 51
4.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 18 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR DIGITAL THERAPEUTICS 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 19 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Increasing incidence of preventable chronic diseases 54
5.2.1.2 Rising focus on preventive healthcare 54
5.2.1.3 Need to control healthcare costs 55
5.2.1.4 Significant increase in venture capital investments 55
5.2.1.5 Benefits of digital therapeutics 56
5.2.1.5.1 Ability to induce behavioral change 56
5.2.1.5.2 Improved drug adherence 56
5.2.1.5.3 Patient convenience and user-friendliness 57
5.2.2 RESTRAINTS 57
5.2.2.1 Patient data privacy concerns 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Emerging markets 57
5.2.3.2 Large undiagnosed and untreated population 58
5.2.3.3 Unexplored therapeutic applications 58

5.2.4 CHALLENGES 58
5.2.4.1 Unstable payment models 58
5.2.4.2 Reluctance among patients to adopt digital therapeutics 59
5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries 59
5.2.4.4 Resistance from traditional healthcare providers 59
5.3 PORTER’S FIVE FORCES ANALYSIS 60
5.3.1 THREAT OF NEW ENTRANTS 60
5.3.2 BARGAINING POWER OF SUPPLIERS 60
5.3.3 BARGAINING POWER OF BUYERS 61
5.3.4 THREAT OF SUBSTITUTES 61
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 61
5.4 VALUE CHAIN ANALYSIS 61
FIGURE 20 VALUE CHAIN ANALYSIS 61
5.5 ECOSYSTEM ANALYSIS 62
FIGURE 21 ECOSYSTEM ANALYSIS 62
5.6 PIPELINE PRODUCTS 63
5.7 TECHNOLOGY TRENDS 64
5.8 CASE STUDIES 65
5.9 REGULATORY LANDSCAPE 65
TABLE 2 DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED
FOR CLASS II DEVICES 66
5.10 IMPACT OF COVID-19 ON THE DIGITAL THERAPEUTICS MARKET 67
6 DIGITAL THERAPEUTICS MARKET, BY APPLICATION 68
6.1 INTRODUCTION 69
TABLE 3 DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 69
6.2 TREATMENT/CARE-RELATED APPLICATIONS 69
TABLE 4 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 70
TABLE 5 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 70
6.2.1 DIABETES 71
6.2.1.1 Rising prevalence of diabetes to drive market growth 71
TABLE 6 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION,
2019–2026 (USD MILLION) 71
6.2.2 CENTRAL NERVOUS SYSTEM DISORDERS 72
TABLE 7 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE,
2019–2026 (USD MILLION) 72
TABLE 8 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION,
2019–2026 (USD MILLION) 72
6.2.2.1 Mental health disorders 72
6.2.2.1.1 Potential benefits of digital therapeutics in mental health disorder management have driven the development of these solutions 72
TABLE 9 DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 73
6.2.2.2 Other CNS disorders 73
TABLE 10 DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2019–2026 (USD MILLION) 74
6.2.3 SMOKING CESSATION 74
6.2.3.1 Focus on providing clinically validated, effective mobile applications to help quit smoking to aid market growth 74
TABLE 11 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2019–2026 (USD MILLION) 75
6.2.4 CHRONIC RESPIRATORY DISEASES 75
6.2.4.1 Growing prevalence of COPD and asthma to drive market growth 75
TABLE 12 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES,
BY REGION, 2019–2026 (USD MILLION) 75
6.2.5 MUSCULOSKELETAL DISORDERS 76
6.2.5.1 Dearth of physiotherapists to support market growth 76
TABLE 13 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 76
6.2.6 CARDIOVASCULAR DISEASE 76
6.2.6.1 High burden of CVD across the globe is the major factor driving the demand for digital therapeutics solutions 76
TABLE 14 DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASE,
BY REGION, 2019–2026 (USD MILLION) 77
6.2.7 MEDICATION ADHERENCE 77
6.2.7.1 Growing number of medication non-adherence cases to propel market growth 77
TABLE 15 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2019–2026 (USD MILLION) 78
6.2.8 GASTROINTESTINAL DISORDERS 78
6.2.8.1 High prevalence of gastrointestinal disorders has attracted many startups in the space of digital health 78
TABLE 16 DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS,
BY REGION, 2019–2026 (USD MILLION) 78
6.2.9 REHABILITATION & PATIENT CARE 79
6.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care 79
TABLE 17 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE,
BY REGION, 2019–2026 (USD MILLION) 79
6.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT 79
6.2.10.1 Potential to improve the efficiency of behavioral interventions to drive market growth 79
TABLE 18 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2019–2026 (USD MILLION) 80
6.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS 80
TABLE 19 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2019–2026 (USD MILLION) 80
6.3 PREVENTIVE APPLICATIONS 81
TABLE 20 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 81
TABLE 21 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY REGION, 2019–2026 (USD MILLION) 82
6.3.1 PREDIABETES 82
6.3.1.1 Influx of startups to provide effective prevention against prediabetes will support market growth 82
TABLE 22 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION,
2019–2026 (USD MILLION) 82
6.3.2 OBESITY 83
6.3.2.1 Availability of cost-effective solutions for obesity management to propel market growth 83
TABLE 23 DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION,
2019–2026 (USD MILLION) 83
6.3.3 NUTRITION 83
6.3.3.1 Importance of nutrition in preventing a wide range of ailments has driven the demand for digital therapeutic solutions 83
TABLE 24 DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION,
2019–2026 (USD MILLION) 84
6.3.4 LIFESTYLE MANAGEMENT 84
6.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes has contributed to the rising demand 84
TABLE 25 DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2019–2026 (USD MILLION) 85
6.3.5 OTHER PREVENTIVE APPLICATIONS 85
TABLE 26 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS,
BY REGION, 2019–2026 (USD MILLION) 86
7 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL 87
7.1 INTRODUCTION 88
TABLE 27 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 88
7.2 B2B 88
TABLE 28 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 88
TABLE 29 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2019–2026 (USD MILLION) 89
7.2.1 PAYERS 89
7.2.1.1 Payers held the largest market share 89
TABLE 30 DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION,
2019–2026 (USD MILLION) 90
7.2.2 EMPLOYERS 90
7.2.2.1 Importance of employee health management has increased the adoption of digital therapeutics among employers 90
TABLE 31 DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION,
2019–2026 (USD MILLION) 91
7.2.3 PHARMACEUTICAL COMPANIES 91
7.2.3.1 Growing cross-industry collaborations between digital therapeutics start-ups and pharmaceutical companies to drive market growth 91
TABLE 32 DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES,
BY REGION, 2019–2026 (USD MILLION) 92
7.2.4 PROVIDERS 92
7.2.4.1 Potential for better patient management and cost-reductions are driving the demand for digital therapeutics among providers 92
TABLE 33 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION,
2019–2026 (USD MILLION) 93
7.2.5 OTHER BUYERS 93
TABLE 34 DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION,
2019–2026 (USD MILLION) 93
7.3 B2C 94
TABLE 35 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 94
TABLE 36 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2019–2026 (USD MILLION) 94
7.3.1 CAREGIVERS 95
7.3.1.1 Ease of managing health conditions has driven the demand for solutions among caregivers 95
TABLE 37 DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION,
2019–2026 (USD MILLION) 95
7.3.2 PATIENTS 95
7.3.2.1 Awareness about preventive health among patients to support the growth of this segment 95
TABLE 38 DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION,
2019–2026 (USD MILLION) 96
8 DIGITAL THERAPEUTICS MARKET, BY REGION 97
8.1 INTRODUCTION 98
TABLE 39 DIGITAL THERAPEUTICS MARKET, BY REGION, 2019–2026 (USD MILLION) 98
8.2 NORTH AMERICA 98
FIGURE 22 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT 99
TABLE 40 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 100
TABLE 41 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 100
TABLE 42 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 101
TABLE 43 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 101
TABLE 44 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS,
BY TYPE, 2019–2026 (USD MILLION) 102
TABLE 45 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2019–2026 (USD MILLION) 102
TABLE 46 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 102
TABLE 47 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 103
8.2.1 US 103
8.2.1.1 Major digital therapeutics start-ups are based out of the US, which has greatly supported access to solutions 103
TABLE 48 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 104
TABLE 49 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 104
TABLE 50 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 105
TABLE 51 US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE,
2019–2026 (USD MILLION) 105
TABLE 52 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 105
TABLE 53 US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 106
TABLE 54 US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 106
8.2.2 CANADA 106
8.2.2.1 Government initiatives to support digital therapeutics to drive market growth in Canada 106
TABLE 55 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 107
TABLE 56 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 57 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 108
TABLE 58 CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 109
TABLE 59 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 109
TABLE 60 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 109
TABLE 61 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 110
8.3 EUROPE 110
FIGURE 23 EUROPE: DIGITAL THERAPEUTICS MARKET SNAPSHOT 111
TABLE 62 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 112
TABLE 63 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 112
TABLE 64 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 65 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 113
TABLE 66 EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 114
TABLE 67 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 114
TABLE 68 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 114
TABLE 69 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 115
8.3.1 GERMANY 115
8.3.1.1 Germany is the largest market for digital therapeutics in Europe due to increasing government initiatives 115
TABLE 70 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 116
TABLE 71 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 116
TABLE 72 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 73 GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 117
TABLE 74 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 117
TABLE 75 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 118
TABLE 76 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 118
8.3.2 UK 118
8.3.2.1 Well-established healthcare system and government support will propel the growth of the market 118
TABLE 77 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 119
TABLE 78 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 119
TABLE 79 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 120
TABLE 80 UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE,
2019–2026 (USD MILLION) 120
TABLE 81 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 120
TABLE 82 UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 121
TABLE 83 UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 121
8.3.3 FRANCE 121
8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market growth in France 121
TABLE 84 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 122
TABLE 85 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 122
TABLE 86 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 87 FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 88 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 123
TABLE 89 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 124
TABLE 90 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 124
8.3.4 SPAIN 124
8.3.4.1 Initiatives by emerging digital therapeutics startups are supporting market growth 124
TABLE 91 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 125
TABLE 92 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 125
TABLE 93 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 94 SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 95 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 126
TABLE 96 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 127
TABLE 97 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 127
8.3.5 ITALY 127
8.3.5.1 Need for alternative and effective treatment to drive the market growth in the coming years 127
TABLE 98 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 128
TABLE 99 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 100 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 101 ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 129
TABLE 102 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 129
TABLE 103 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 130
TABLE 104 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 130
8.3.6 REST OF EUROPE 130
TABLE 105 ROE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 131
TABLE 106 ROE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 131
TABLE 107 ROE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 108 ROE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 109 ROE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 132
TABLE 110 ROE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 133
TABLE 111 ROE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 133
8.4 ASIA PACIFIC 133
TABLE 112 APAC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY,
2019–2026 (USD MILLION) 134
TABLE 113 APAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 134
TABLE 114 APAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 115 APAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 116 APAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 136
TABLE 117 APAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 136
TABLE 118 APAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 136
TABLE 119 APAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 137
8.4.1 JAPAN 137
8.4.1.1 Rising diabetes incidence and collaborations between stakeholders are indicators of market growth in Japan 137
TABLE 120 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 137
TABLE 121 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 138
TABLE 122 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 138
TABLE 123 JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 139
TABLE 124 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 139
TABLE 125 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 139
TABLE 126 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 140
8.4.2 CHINA 140
8.4.2.1 The growing geriatric population and incidence of chronic conditions will drive demand for digital therapeutics in China 140
TABLE 127 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 140
TABLE 128 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 129 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 141
TABLE 130 CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 142
TABLE 131 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 142
TABLE 132 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 142
TABLE 133 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 143
8.4.3 INDIA 143
8.4.3.1 Rising chronic disease incidence and the need for better disease management drive market growth 143
TABLE 134 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 144
TABLE 135 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 144
TABLE 136 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 137 INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 138 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 145
TABLE 139 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 146
TABLE 140 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 146
8.4.4 REST OF APAC 146
TABLE 141 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 147
TABLE 142 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 147
TABLE 143 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 144 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 145 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 148
TABLE 146 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 149
TABLE 147 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL,
BY BUYER, 2019–2026 (USD MILLION) 149
8.5 REST OF THE WORLD 149
TABLE 148 ROW: DIGITAL THERAPEUTICS MARKET, BY APPLICATION,
2019–2026 (USD MILLION) 150
TABLE 149 ROW: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2019–2026 (USD MILLION) 150
TABLE 150 ROW: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS,
BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 151 ROW: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS,
BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 152 ROW: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL,
2019–2026 (USD MILLION) 151
TABLE 153 ROW: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 152
TABLE 154 ROW: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2019–2026 (USD MILLION) 152
9 COMPETITIVE LANDSCAPE 153
9.1 OVERVIEW 153
FIGURE 24 KEY PLAYERS ADOPTED ORGANIC AS WELL AS INORGANIC GROWTH STRATEGIES BETWEEN 2016 AND 2021 153
9.2 MARKET RANKING ANALYSIS, 2021 154
FIGURE 25 DIGITAL THERAPEUTICS MARKET RANKING ANALYSIS, 2021 154
9.3 COMPANY EVALUATION MATRIX 155
9.3.1 INTRODUCTION 155
9.3.2 COMPANY EVALUATION MATRIX: DEFINITIONS AND METHODOLOGY 155
9.3.2.1 Stars 155
9.3.2.2 Emerging leaders 155
9.3.2.3 Pervasive players 156
9.3.2.4 Emerging companies 156
FIGURE 26 DIGITAL THERAPEUTICS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2021 156
9.3.3 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES (2021) 157
9.3.3.1 Progressive companies 157
9.3.3.2 Starting blocks 157
9.3.3.3 Responsive companies 157
9.3.3.4 Dynamic companies 157
FIGURE 27 DIGITAL THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021 158
9.4 COMPETITIVE SCENARIO 159
9.4.1 DEALS 159
TABLE 155 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2016 TO JUNE 2021 159
9.4.2 PRODUCT LAUNCHES 161
TABLE 156 DIGITAL THERAPEUTICS MARKET: PRODUCT LAUNCHES,
JANUARY 2016 TO JUNE 2021 161
9.4.3 EXPANSIONS 162
TABLE 157 DIGITAL THERAPEUTICS MARKET: EXPANSIONS, JANUARY 2016 TO JUNE 2021 162

10 COMPANY PROFILES 163
(Business Overview, Products Offered, Recent Developments, MnM View)*
10.1 NOOM, INC. 163
10.2 LIVONGO HEALTH 164
10.3 OMADA HEALTH 166
10.4 COGNIFIT 168
10.5 WELLDOC 170
10.6 GINGER 172
10.7 PROPELLER HEALTH 173
10.8 2MORROW, INC. 174
10.9 CANARY HEALTH 175
10.10 MANGO HEALTH, INC. 176
10.11 CLICK THERAPEUTICS 177
10.12 PEAR THERAPEUTICS 178
10.13 AKILI INTERACTIVE LABS, INC. 181
10.14 WELLTHY THERAPEUTICS 182
10.15 COGNOA, INC. 183
10.16 HAPPIFY 184
10.17 KAIA HEALTH 185
10.18 AYOGO HEALTH 187
10.19 BETTER THERAPEUTICS 188
10.20 MINDSTRONG HEALTH 189
10.21 BEHAVR INC. 190
10.22 MINDABLE HEALTH 192
10.23 VIRTA HEALTH 193
10.24 HINGE HEALTH 194
10.25 DOKTOR.SE 196
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
11 APPENDIX 197
11.1 DISCUSSION GUIDE 197
11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 201
11.3 AVAILABLE CUSTOMIZATIONS 203
11.4 RELATED REPORTS 203
11.5 AUTHOR DETAILS 204



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(HIT4407 )"デジタルセラピューティクス(DTx)の世界市場(~2026年):用途別(前糖尿病、栄養、ケア、糖尿病、CVD、CNS、CRD、MSD、GI、薬物乱用、リハビリテーション)、販売チャネル別(B2C、患者、介護者、B2B、提供者、支払者、雇用者、製薬会社)" (英文:Digital Therapeutics (DTx) Market by Application (Prediabetes, Nutrition, Care, Diabetes, CVD, CNS, CRD, MSD, GI, Substance Abuse, Rehabilitation), Sales Channel (B2C, Patient, Caregiver, B2B, Providers, Payer, Employer, Pharma) - Global Forecasts to 2026)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。